Suzano (SUZB3) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
12 Nov, 2025Strategic rationale and transaction structure
Suzano will control a new joint venture with Kimberly-Clark, holding 51% ownership and appointing the majority of the board, CEO, and CFO, with a call option to acquire the remaining 49% after three years at a pre-agreed multiple.
The JV covers 14 countries, 22 facilities, and will be headquartered in the Netherlands, operating independently from Suzano's core business.
The partnership combines Suzano's industrial expertise with Kimberly-Clark's commercial and branding strengths, aiming to accelerate the fiber-to-fiber strategy in the global tissue market.
The JV will have access to global and local premium brands, including a 30-year royalty-free license for Kleenex, Scott, Andrex, and 40 local brands.
The deal is expected to close by mid-2026, pending regulatory approvals, with signing and payment expected by June 4, 2025, and integration planning underway.
Financial impact and synergies
The transaction values the business at $3.4 billion enterprise value, with a potential $1 billion in net debt at closing, reducing Suzano's equity disbursement to $1.2 billion; acquisition value is set at USD 1.734 billion.
Expected annual revenues are $3.3 billion, EBITDA $500 million, and free cash flow generation around $300 million.
Estimated operational synergies of $175 million per year to be fully realized within three years, mainly from procurement, industrial efficiencies, logistics, and G&A, with no major CapEx required.
The JV is expected to deliver an IRR above 15%, with efficiency gains modeled conservatively compared to prior Brazilian operations; expected unleveraged IRR is 15.5% in US dollar nominal terms.
The transaction is designed to have limited impact on leverage, maintain Suzano’s investment-grade status, and reduce cash flow volatility.
Business overview and operational footprint
The joint venture will have 1.0 million tons of tissue capacity, 22 mills in 14 countries, and sales in over 70 countries.
The business will operate in two segments: Family Care and Professional.
Revenue distribution is diversified across EMEA, UK, Latin America, Asia, and Oceania.
The JV will operate with an average annual sustained CapEx of $100 million.
No changes are expected in Suzano’s pulp inventory management as the JV will operate independently.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025